UAE Atherosclerosis Therapeutics Market Analysis

UAE Atherosclerosis Therapeutics Market Executive Summary

UAE Atherosclerosis Therapeutics Market was valued at $14 Mn in 2022 and is estimated to reach $24 Mn in 2030, exhibiting a CAGR of 6.7% during the forecast period.

Vascular constriction or blockage caused by plaque buildup is known as atherosclerosis. The plaque that is created by the combination of poor cholesterol and white blood cells might disrupt the body's normal blood flow. Damage to the inner lining of the blood vessel facilitates the attachment of dangerous cholesterol to the vessel walls. Plaque forms when the body's natural removal mechanism, cells, gets stuck from time to time. It is possible for this plaque to clog the channel, reducing blood flow and increasing the risk of potentially fatal conditions such as heart attacks and strokes. Several things can contribute to atherosclerosis, such as high blood pressure, high cholesterol, diabetes, obesity, smoking, heart disease in the family, inactivity, and eating an unhealthy diet.

The prevalence of atherothrombotic cardiovascular disease (ASCVD) is 20.9% in the United Arab Emirates. Additionally, men have greater rates (26.6%) than do women (15.2%). Young adults in the United Arab Emirates have a high prevalence of cardiometabolic risk factors, which may indicate a higher chance of developing atherosclerosis in the future. A higher vulnerability to atherosclerosis is caused by several risk factors, including high blood pressure, high cholesterol, diabetes, smoking, and obesity. All of these risks are rather frequent in the UAE. Based on variables including age, gender, socioeconomic position, and lifestyle choices, the prevalence of atherosclerosis is probably going to differ among the people in the United Arab Emirates.

Pfizer has effectively secured regulatory approval in the United Arab Emirates for Inclisiran (Orlivayo), a novel RNAi medication intended to reduce cholesterol levels in individuals at high risk. This milestone represents a significant step forward in the provision of long-term therapeutic options.

Novartis has declared that Leqvio (Inclisiran) has been approved in the United Arab Emirates for its affiliated Medicines Company, expanding the availability of this cutting-edge medical treatment.

Market Dynamics

Market Growth Drivers

Increasing Cardiovascular Disease Burden: The United Arab Emirates (UAE) has a high incidence of cardiovascular disease (CVD), with 30% of people estimated to have at least one cardiovascular risk factor. Atherosclerosis, a primary contributor to CVD, is significantly contributing to the growing demand for various treatment alternatives. In addition to increasing the burden of CVD, the rising prevalence of risk factors such as diabetes, high blood pressure, and unhealthy cholesterol levels also increases the need for better atherosclerosis treatment techniques.

Aging Population: The aging of the population contributes significantly to the elderly's increased susceptibility to atherosclerosis, which has increased the demand for atherosclerosis-related therapeutics. By 2050, the elderly population in the United Arab Emirates is expected to have grown five times, making up almost 16% of the overall population. As a result, there will be more than 2 Mn adults over 65, up from the present estimate of about 150,000. The aging population's increased vulnerability to atherosclerosis highlights the growing need to address treatment needs associated with this cardiovascular disease.

Advancements in Drug Development: Innovative drugs like PCSK9 inhibitors and inclisiran, which lower cholesterol using RNA interference therapy, offer more and better treatment options, which is driving the market's expansion. There are opportunities for market expansion due to the growing emphasis on customized treatment plans that take into account individual patient profiles and genetic susceptibilities to atherosclerosis.

Market Restraints

Cost and Affordability: The cost of several drugs used to treat atherosclerosis makes them unaffordable for a substantial segment of the population, especially those with lower incomes or less access to healthcare. This makes high prescription drug prices a concern. This hinders overall growth and restricts market penetration.

Patient Adherence: Long-term drug adherence is typically necessary for effective treatment of atherosclerosis, which can be difficult for some people. Non-adherence can result from a variety of factors, including unfavourable side effects, complex dose regimens, and a lack of evident instant benefits. If challenges develop, this could reduce the efficacy of treatment and raise medical expenses.

Regulatory Hurdles: Pharmaceutical companies may encounter difficulties and pay additional expenditures as a result of lengthy clinical trials and strict regulatory procedures, delaying the timely introduction of new drugs onto the market. Businesses may experience uncertainty as a result of unclear regulations that govern regulatory procedures, which can make it challenging for them to plan for approval dates and manage the system efficiently.

Healthcare Policies and Regulatory Landscape

The Ministry of Health and Prevention (MOHAP) is the principal regulating body for therapeutics in the United Arab Emirates (UAE). It is responsible for guaranteeing the efficacy, safety, and calibre of healthcare services and goods, including medicines, throughout the nation. The Drug Control Department of MOHAP conducts a rigorous examination process before approving and registering pharmaceuticals in the United Arab Emirates. This review evaluates the drug's effectiveness, safety profile, and regulatory compliance, among other things. The goal of the registration procedure is to safeguard public health by guaranteeing that only secure and efficient pharmaceuticals are sold.

Competitive Landscape

Key Players

• Pfizer
• Novartis
• AstraZeneca
• Sanofi
• Bayer
• Abbott
• Johnson & Johnson
• Teva Pharmaceutical
• Roche
• Merck & Co.